Literature DB >> 9152975

Medulloblastoma in a patient successfully treated for immature teratoma of the ovary.

S Yalçin1, N Güler, F Söylemezoğlu.   

Abstract

We report a case of medulloblastoma as a secondary malignancy in a patient treated for immature teratoma of the ovary (ITO). ITO is a rare but curable tumor of the ovary using combination chemotherapy. There is a great deal of interest in the long-term effects of chemotherapy in these patients. Once regarded as fatal not many series of patients with ITO have been reported with the long follow up as in the present case. This case may start a debate on the susceptibility of central nervous system tumors following chemotherapy in patients with ITO.

Entities:  

Mesh:

Year:  1996        PMID: 9152975     DOI: 10.1007/bf02990937

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  4 in total

1.  Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases.

Authors:  H J Norris; H J Zirkin; W L Benson
Journal:  Cancer       Date:  1976-05       Impact factor: 6.860

2.  Incidence of second malignant neoplasms in children: results of an international study.

Authors:  V Miké; A T Meadows; G J D'Angio
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

3.  Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy.

Authors:  M B Smith; H Xue; L Strong; H Takahashi; N Jaffe; H Ried; H Zietz; R J Andrassy
Journal:  J Pediatr Surg       Date:  1993-10       Impact factor: 2.545

4.  Patterns of multiple primary tumours in patients treated for cancer during childhood.

Authors:  J E Kingston; M M Hawkins; G J Draper; H B Marsden; L M Kinnier Wilson
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

  4 in total
  1 in total

1.  [Meningothelial meningioma in a mature cystic teratoma of the ovary].

Authors:  H Adams; P Went; M Tolnay; G Sartorius; G Singer
Journal:  Pathologe       Date:  2007-07       Impact factor: 0.973

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.